MannKind Corp
NASDAQ:MNKD

Watchlist Manager
MannKind Corp Logo
MannKind Corp
NASDAQ:MNKD
Watchlist
Price: 5.94 USD Market Closed
Market Cap: 1.8B USD

Net Margin
MannKind Corp

9.2%
Current
-21%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
9.2%
=
Net Income
28.8m
/
Revenue
313.8m

Net Margin Across Competitors

No Stocks Found

MannKind Corp
Glance View

Market Cap
1.8B USD
Industry
Biotechnology

MannKind Corp. stands as a fascinating player in the biotech landscape, primarily due to its focus on innovative drug delivery systems that aim to redefine patient experience and therapeutic efficacy. Founded with the intention of creating transformative medicinal solutions, the company is best known for its flagship product, Afrezza, an inhalable form of insulin designed to manage diabetes. This unique delivery method not only enhances the speed at which insulin begins to act within the body, but also offers a discreet and user-friendly alternative to traditional injectable options. Driven by a blend of science and practicality, MannKind's efforts are centered around enhancing quality of life for patients, marking its territory in a niche, yet crucial, segment of the pharmaceutical market. MannKind generates revenue by producing and distributing its highly specialized products, leveraging partnerships with larger pharmaceutical companies to expand its market reach. By optimizing their drug delivery systems, they aim to position themselves competitively, offering solutions that stand out in a crowded industry. Beyond Afrezza, MannKind seeks to harness its proprietary Technosphere technology platform, exploring applications beyond diabetes to potentially treat other conditions. This approach not only broadens their market horizon but also diversifies potential revenue streams, allowing MannKind to maintain a steady course in the volatile currents of the biotech sector. In essence, MannKind's business strategy is a calculated blend of ingenuity and collaboration, with a clear emphasis on meeting unmet medical needs effectively.

MNKD Intrinsic Value
5.22 USD
Overvaluation 12%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
9.2%
=
Net Income
28.8m
/
Revenue
313.8m
What is the Net Margin of MannKind Corp?

Based on MannKind Corp's most recent financial statements, the company has Net Margin of 9.2%.

Back to Top